Back to search

Boston University

Optimization of delivery of TGF-beta for improving quality of engineered articular cartilage

Abstract

dc:description.abstract

Osteoarthritis (OA) is a painful, debilitating condition that results from the mechanical degeneration of articular cartilage. Cartilage tissue engineering is a promising OA therapy, whereby chondrogenic cells are encapsulation in a hydrogel scaffold and cultivated in vitro in an attempt to create a suitable replacement tissue. Transforming growth factor-beta (TGF-b) is a highly anabolic hormone that has served as one of the most prominent cartilage growth mediators, promoting the development of engineered tissues with native levels of mechanical properties and biochemical contents. In cartilage tissue engineering, TGF-b is conventionally administered supplemented in culture medium with the expectation that it will readily diffuse into tissue constructs. However, recent evidence has brought to light severe limitations with this approach when attempting to generate engineered cartilage of sufficient size to repair clinical OA defects (10-25mm), as mediasupplemented TGF-b exhibits vast transport limitations in constructs, giving rise to undesirable, highly heterogeneous cartilage formation. Consequently, a long-term goal of our research group is to develop novel TGF-b chemical delivery strategies that achieve improved uniformity of its activity in the tissue. Critically, the development of these strategies require a fundamental understanding of the optimal delivery profile (exposure concentration and duration) of TGF-b activity to achieve optimal cartilage tissue growth. Interestingly, while low doses of TGF-b are typically associated with insufficient growth and matrix deposition, supraphysiologic doses are associated with the induction of pathological tissue features, such as fibrosis, chondrocyte hypertrophy and the clustering of chondrocytes in a phenotype that does not resemble healthy articular chondrocytes. Here we perform this characterization by examining the effect of near physiologic doses (0.1- 1ng/mL) and supraphysiologic doses (3-100ng/mL) of TGF-b on constructs growth. Further, we exposed tissue constructs to varying temporal delivery profiles. Results demonstrate that, interestingly, physiologic TGF-b doses (0.1-1 ng/mL) induce the formation of engineered cartilage with native mechanical properties (350-780 kPa) but with improved tissue quality, as marked by more isolated chondrocytes that resemble the phenotype of native cartilage. These results pave the path for the future development of large sized engineered cartilage tissues, whereby, physiologic levels can be delivered uniformly throughout the tissue via biomaterial delivery strategies.

Degree

thesis:*
Name thesis:degree_name
Master of Science
Level thesis:degree_level
masters
Discipline thesis:degree_discipline
Materials Science & Engineering
Grantor
Boston University
Year dc:date.issued
2018

Author and committee

dc:creator, dc:contributor.*
Author dc:creator
  • Wang, Tianbai
Advisor dc:contributor.advisor
  • Albro, Michael B.

Subjects

dc:subject × 1

Rights

Language dc:language.iso
en_US

Identifiers

dc:identifier.*
Handle dc:identifier.uri
https://hdl.handle.net/2144/30734

Chain of custody

source
Harvested from
Boston University
Base URL
open.bu.edu/oai/request
Last updated
2026-11-19
Source record
OAI-PMH GetRecord
citation

Wang, Tianbai. Optimization of delivery of TGF-beta for improving quality of engineered articular cartilage. masters thesis, Boston University, 2018. https://hdl.handle.net/2144/30734